Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 650482, 6 pages
http://dx.doi.org/10.5402/2011/650482
Review Article

“Il Corpo Ritrovato”: Dermocosmetological Skin Care Project for the Oncologic Patient

1Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II, Street Sergio Pansini 5, Naples 80133, Italy
2ASL ROMA C and Division of Clinical Dermatology, University of Rome “Tor Vergata”, 00133 Rome, Italy
3Surgery of Aesthetic Dermatology of San Gallicano Dermatological Institute (IRCCS), 00118 Rome, Italy

Received 2 February 2011; Accepted 15 March 2011

Academic Editor: A. Sella

Copyright © 2011 G. Fabbrocini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Carelle, E. Piotto, A. Bellanger, J. Germanaud, A. Thuillier, and D. Khayat, “Changing patient perceptions of the side effects of cancer chemotherapy,” Cancer, vol. 95, no. 1, pp. 155–163, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Zenger, H. Glaesmer, M. Höckel, and A. Hinz, “Pessimism predicts anxiety, depression and quality of life in female cancer patients,” Japanese Journal of Clinical Oncology, vol. 41, no. 1, pp. 87–94, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. J. Ciarrochi, D. Fisher, and L. Lane, “The link between value motives, value success, and well-being among people diagnosed with cancer,” Psychooncology. In press.
  4. N. Heidary, H. Naik, and S. Burgin, “Chemotherapeutic agents and the skin: an update,” Journal of the American Academy of Dermatology, vol. 58, no. 4, pp. 545–570, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. E. Lacouture, M. L. Maitland, S. Segaert et al., “A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group,” Supportive Care in Cancer, vol. 18, no. 4, pp. 509–522, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. R. Pérez-Soler, “Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?” Oncology (Williston Park, N.Y.), vol. 17, no. 11, pp. 23–28, 2003. View at Google Scholar · View at Scopus
  7. R. M. Trüeb, “Chemotherapy-induced alopecia,” Seminars in Cutaneous Medicine and Surgery, vol. 28, no. 1, pp. 11–14, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. Tosti et al., “Permanent Chemotherapy-Induced Alopecia: A Review,” Journal of the American Academy of Dermatology, vol. 64, no. 3, pp. 604–606, 2011. View at Google Scholar
  9. N. Salvo, E. Barnes, J. van Draanen et al., “Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature,” Current Oncology, vol. 17, no. 4, pp. 94–112, 2010. View at Google Scholar
  10. F. Scotté, J. M. Tourani, E. Banu et al., “Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4424–4429, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Duvic, N. A. Lemak, V. Valero et al., “A randomized trial of minoxidil in chemotherapy-induced alopecia,” Journal of the American Academy of Dermatology, vol. 35, no. 1, pp. 74–78, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Bulow, L. Friberg, O. Gaardsting, and M. Hansen, “Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 45, no. 6, pp. 505–508, 1985. View at Google Scholar · View at Scopus